The Story of AKIGAI
Like many breakthroughs in the history of medicine, relief of neuropathic pain after treatment with an EGFR-inhibitor was a serendipitous discovery.
More about AKIGAI's story
The Science
The EGFR is one of the most studied molecules in the human body.
The science behind AKIGAI's approach
About AKIGAI
AKIGAI is a biotech-startup whose founders hold global use patents for a drug class that has been given to millions of people for over 20 years.
Our Strategy
The two routes of administration
AKIGAI's approach is twofold. We envision two paths to development of a new type of EGFR-inhibitor.
Learn about AKIGAI's strategy
Collaborate with AKIGAI
AKIGAI is looking for partners and collaborators to help realize EGFR-inhibitors for use against neuropathic pain.
More about collaborations
We are proud to be
working with
